Publication date: Nov 06, 2019
Getty To fulfill its promise precision medicine requires accurate decision support tools, especially to streamline biomarker testing so that the appropriate targeted therapies are prescribed.
Even in oncology, where precision medicine has advanced the farthest compared to other therapeutic categories, clinical decision tools are needed to sort through and analyze reams of clinical and molecular data for the purpose of optimizing treatment algorithms.
Elsevier’s Via Oncology, for example, operates a clinical decision support tool called Via Pathways, designed to inform the appropriate use of biomarker tests and corresponding targeted therapies.
According to recently released precision medicine cancer treatment clinical trial Molecular Analysis for Therapy Choice (MATCH) only 15% of common tumors tested have actionable mutations.
Other companies that focus on clinical decision support tools, such as Tempus, are attempting to harness the power of AI.
Here, clinical decision tools, AI, and Big Data are changing the landscape.
|pathway||BSID||Non-small cell lung cancer|
|disease||DOID||non-small cell lung cancer|
|disease||MESH||non-small cell lung cancer|
- Building the Team to Decode Biology with Tina Larson | Talking Precision Medicine #16
- How Artifical Intelligence Is Advancing Precision Medicine
- Moving Forward with Biomarkers in Precision Medicine – 2nd Int Congress on Precision Nedicine, Munich, Alain van Gool
- Amplion’s Machine Learning Platform Accelerates Precision Medicine Collaboration
- An integrated clinical and genomic information system for cancer precision medicine.